HCW Reiterates ONCY Buy
H.C. Wainwright maintains buy rating on Oncolytics Biotech stock. No change to estimates.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.
Related stories
Republic Airways Reports Q3 Revenue of $553.5M
M impact | EQUITY | Oct 29, 2026, 11:19 AM UTC
Harley-Davidson Reports Third-Quarter Results, Raises Full-Year Guidance
Harley-Davidson reported third-quarter 2026 results and raised its HDMC and HDFS full-year guidance for the second time this year.
M impact | EQUITY | Oct 29, 2026, 11:11 AM UTC
Telesat Reports Third-Quarter Loss of C$3.09 Per Share
M impact | EQUITY | Oct 29, 2026, 11:10 AM UTC
First Mid Bancshares Q3 earnings snapshot
M impact | EQUITY | Oct 29, 2026, 11:10 AM UTC
Allegro MicroSystems Reports Q2 Revenue of $276.9M
Q2 revenue was $276.9 million, versus a FactSet estimate of $270.9 million.
M impact | EQUITY | Oct 29, 2026, 11:10 AM UTC
Pagaya forecasts Q4 total revenue and other income of USD 355-405 million
M impact | EQUITY | Oct 29, 2026, 11:10 AM UTC